Exenatide Affected Circulating Cardiovascular Risk Biomarkers Independently Of Changes In Body Composition

  1. U. Smith, MD, PhD, FRCPd
  1. aDepartment of Internal Medicine, Section of Endocrinology, Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands
  2. bDepartment of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  3. cMinerva Medical Research Institute, Helsinki, Finland
  4. dLundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Goteborg, Sweden
  5. eEli Lilly and Company, Indianapolis, IN, United States
  6. fEli Lilly and Company, Houten, the Netherlands


Objective To study the effect of exenatide (Ex) on body composition and circulating cardiovascular risk biomarkers.

Research Design and Methods Metformin-treated patients with T2D (N=69) were randomized to exenatide (Ex) or insulin glargine (IG) and treated for one-year. Body composition was evaluated by Dual-Energy X-ray Absorptiometry. Additionally, body weight, waist circumference and cardiovascular biomarkers were measured.

Results One-year treatment with Ex significantly reduced body weight, waist circumference, total body and trunkal fat mass by 6%, 5%, 11% and 13%, respectively. In addition, Ex increased total adiponectin by 12%, and reduced hsCRP by 61%. IG significantly reduced endothelin-1 by 7%. These changes were statistically independent of the change in total body fat mass and body weight.

Conclusions Ex treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with IG except a trend for reduced endothelin-1 levels.


    • Received December 25, 2009.
    • Accepted April 20, 2010.